Home | Pharmaceutical Outsourcing - The Journal of Pharmaceutical & Biopharmaceutical Contract Services

From Service Provider to Strategic Partner
As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability read more
Flexibility as a Core IND Strategy
With the increasing complexities of current IND programs, it is critical to work with regulatory agencies to seek input early in the process. read more
The Operational Foundations That Characterize Regulatory Leaders
Holding individuals and teams explicitly accountable for data accuracy and quality might seem straightforward, but it is difficult to sustain in practice. read more
Leveraging AI and ML to Optimize Drug Discovery – a CRO Perspective
CROs supporting early-stage drug discovery projects are establishing their own internal AI platforms to address their clients’ needs in an evolving field. read more

Clinical Trials - Transforming Drug Development
Transforming Drug Development: Accelerating Clinical Trials through Patient-Centric Innovations and Technological Breakthroughs Watch Now

Bora, Onconic Ink Manufacturing Deal for U.S. JAQBO Clinical Program
Thursday, July 23, 2026
Bora Pharmaceuticals and Onconic Therapeutics have signed a manufacturing agreement to support the U.S. clinical development of JAQBO tablets, a ... read more
ImmuPharma Selects Thermo Fisher Scientific Drug Product CDMO for Kapiglucagon Program
Wednesday, July 22, 2026
The selection of Thermo Fisher represents an important Chemistry, Manufacturing and Controls (“CMC”) milestone for the Kapiglucagon program and is ... read more
Restore Vision and Forge Biologics Announce AAV Development and cGMP Manufac-turing Partnership
Wednesday, July 22, 2026
Restore Vision and Forge Biologics, a manufacturer of gene therapies and member of Ajinomoto Bio-Pharma Services, announced a development and ... read more
Wheeler Bio Appoints Chief Development Officer
Wednesday, July 22, 2026
Wheeler Bio announced the appointment of Rajesh Beri, Ph.D., as Chief Development Officer. read more
Phanes, Merck Expand Trial Pact to Test CD47 Bispecific with KEYTRUDA in 1L Biliary Tract Cancer
Tuesday, July 21, 2026
Phanes Therapeutics has expanded its clinical trial collaboration and supply agreement with Merck to evaluate spevatamig in combination with KEYTRUDA ... read more